Breast Cancer Alliance provides seed money – scientific venture capital – to fund innovative breast cancer research with emphases on programs that have not yet qualified for federal grants. To secure federal funding, a researcher must prove a theory works. Breast Cancer Alliance creates the critical bridge between novel research and the opportunity to generate preliminary results with grants like our Exceptional Projects.
BCA encourages careers in breast cancer research and in clinical medicine. We award two year Young Investigator Grants to doctors and scientists in the early stages of their careers, often overlooked by the funding world until they have longer tenure. We also fund Breast Surgery Fellowships at Society of Surgical Oncology accredited institutions providing specialized post-graduate training in breast surgery. Ultimately, these physicians go on to improve both survival rates and quality of life for those they treat, often in parts of the country previously lacking this expertise. Our commitment to education and outreach is evident throughout Connecticut and Westchester County, NY. Each year, we allocate up to twenty-five percent of our funding to help underserved women access breast health care by lessening the financial burden which is often an obstacle to critical exams.
We are committed to transparency, both in how we allocate our funding and in how that funding is utilized. While we require stringent reporting from every one of our grantees, what distinguishes us from other foundations is that we visit each of our grantees to hear about the impact of our allocations firsthand. All of our supporters, and those interested in learning more about BCA, are welcome. If you would like to attend any of these visits, to be held on Zoom in 2021, please email email@example.com.
**Times noted are all EST
July 15, 1pm: Jianua Yu, PhD, An oncolytic virus-engineered to express a full-length anti-CD47 lgG1 antibody for the treatment of breast cancer brain metastasis and Colt Egelston, PhD, City of Hope, Tumor-derived T cell receptors for engineered T cell therapy of breast cancer, Supported by Jane and Stuart Weitzman in memory of Irma Wallin
July 20, 10am Scott Abrams, PhD and Michael Nemeth, Roswell Park, Unique combination immunotherapy to confront triple negative breast cancer
July 20, 11am Rumela Chakrabarti, PhD, University of Pennsylvania, A novel combination immunotherapy to improve treatment of metastatic triple negative breast cancer, Deborah G. Black Memorial Research Grant
June 30, 10am: Dr. Angeleke Saridakis, Yale
July 16, 10am: Dr. Sarah Ponto Shubeck, Memorial Sloan Kettering Cancer Center,
July 16, 11am: Dr. Michelle Abghari, Rutgers Cancer Institute of New Jersey
9:30am: Danbury Hospital/New Milford Hospital, Paula L. Banwell Memorial Grant
10:15am: Norwalk Hospital
9:30am: Greenwich Hospital
10:15am: Yale New Haven Hospital
10:45am: Norma F. Pfriem Breast Cancer Center
10am: Hartford Hospital
10:30am: Griffin Hospital
11am: Griffin Hospital
9:30am: Middlesex Hospital
10am: Stamford Hospital
10:30am: White Plains Hospital